Oncoloxía médica
Servizo
![Foto de Oncoloxía médica](/img/noimage.png)
![Foto de Hospital Ramón y Cajal](/img/noimage_org.png)
Hospital Ramón y Cajal
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Ramón y Cajal (133)
2024
-
Access to melanoma drugs in Spain: a cross-sectional survey
Clinical and Translational Oncology
-
Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738
-
First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN
Breast Cancer Research and Treatment
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432
-
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356
-
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
JAMA network open, Vol. 7, Núm. 4, pp. e247811
-
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study
European urology oncology, Vol. 7, Núm. 3, pp. 447-455
-
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Clinical and Translational Oncology
2023
-
A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2911-2925
-
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
Prostate, Vol. 83, Núm. 4, pp. 376-384
-
Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer
Thrombosis Research, Vol. 232, pp. 133-137
-
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib
Clinical Genitourinary Cancer, Vol. 21, Núm. 3, pp. e166-e174
-
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
Annals of Oncology, Vol. 34, Núm. 5, pp. 468-476
-
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
European Journal of Cancer, Vol. 182, pp. 3-14
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
-
The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study
Cancers, Vol. 15, Núm. 11
-
Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer
Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 882-896
-
Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer
Clinical and Translational Oncology, Vol. 25, Núm. 4, pp. 897-911
-
Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma
Cancer, Vol. 129, Núm. 16, pp. 2581-2592